+17%

est. 2Y upside i

HealthcareSeries B

Rank

#1677

Sector

Healthcare Technology

Est. Liquidity

~4Y

Data Quality

Data: Low

AmplifyMD offers a moderate expected upside of ~16.5% over 2 years, but high uncertainty due to missing key financial data and a severe preference stack.

Last updated: July 19, 2026

Bull (25%)+97%

Exit multiple holds at 7x on $33.75M revenue (implied $236M exit). IPO window or category leadership expands multiple; common stock valued at $141.75M, up 96.9% from $72M entry common.

Base (55%)+13%

Exit multiple converges to 4x (mid of comp range), exit value $135M. Preferred converts, common gets $81M, 12.5% upside from $72M entry common.

Bear (20%)-73%

Multiple compresses to 2x, exit value $67.5M. Preferred takes $48M liquidation preference, common recovers $19.5M (72.9% loss from $72M entry common).

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

27430%

Total funding $48M vs estimated valuation $120M yields 40% preference overhang; common equity is heavily subordinated.

Dilution Risk

low

No near‑term raise expected given $20M raised in Sep 2025 and $48M total; future dilution likely only from option pools.

Secondary Liquidity

none

No known secondary market or tender offers for employee shares.

Questions to Ask at the Interview

Strategic questions based on Amplify MD's data — designed to show you've done your homework.

  • 1

    “How does AmplifyMD's deep EHR integration and multi‑specialty network create a competitive moat against Teladoc and Amwell?”

  • 2

    “What is the average contract value and renewal rate for your health system customers?”

  • 3

    “Can you share the current cap table, option pool size, and any secondary liquidity programs for employees?”

Community

Valuation Sentiment

Our model estimates +17% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.